HC Wainwright

These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Coinbase Global Is 'Doing Almost Everything Right': 7 Analysts React To Q1 Results
Coinbase Q1 Earnings Preview: What Analysts Are Saying, SEC Regulation & Other Items To Watch
Coinbase Global Is 'Doing Almost Everything Right': 7 Analysts React To Q1 Results
Coinbase Q1 Earnings Preview: What Analysts Are Saying, SEC Regulation & Other Items To Watch
'Crypto Winter Is Over': Coinbase Analyst Foresees Market Share Domination In 2023
Why This PepGen Analyst Is Bullish On The Biotech Stock

HC Wainwright Recent News

Why Plug Power Analysts Are Bullish After Hydrogen Green Energy Company's Investor Day
Plug Power Inc. (NASDAQ: PLUG) announced an acquisition, partnerships, products and updated guidance at its 2021 Plug Symposium.
Psyched: Field Trip Gets $20 Price Target, DEA Seeks To Increase Psilocybin Production Limits, Synthesis Closes $7.25M Series A
Contents
Field Trip Stock Could Climb 300% In One Year
On Wednesday, HC WainWright began coverage of Field Trip Health (NASDAQ: FTRP), a company in the psychedelics space, which is developi
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m.
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp.
Wall Street Analysts See These 4 Stocks As Winners Moving Into December
The advancements with COVID-19 vaccines of Pfizer Inc. (NYSE: PFE), Moderna Inc. (NASDAQ: MRNA), and AstraZeneca Inc. (NASDAQ:
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio
HC Wainwright Hikes Karyopharm Price Target On Accelerated Drug Approval
G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
Sell-Side Analysts See Upside Potential In Zynerba
HC Wainwright: Celyad's CAR-T Pipeline Has Potential
HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets
Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity
Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside
Analysts See 100% Upside To Rigel After Tavalisse Approval
HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold
For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'
Analyst Remains Confident In Corium Despite Bad FDA News
Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together'